Expert Opinion on Therapeutic Patents

About the Journal

Journal cover

Editor in Chief: Claudiu T Supuran, University of Florence, Italy

Commissioning Editor: Emma Luscombe

2012 ISI Impact Factor: 3.525

ISSN: 1354-3776 (print), 1744-7674 (electronic)

Early Online

Latest News

  • Carbonic anhydrase inhibitors continue to be a hot topic!

    April 22, 2022
    Carbonic anhydrase inhibitors (CAIs) have been a particularly hot topic recently, with a comprehensive review of the safety aspects associated with these drugs when used to treat different diseases published in Expert Opinion on Drug Safety in the April issue. 
  • Review on small-molecule inhibitors of histone deacetylase chosen as April Editor’s Pick!

    March 26, 2022
    Claudiu Supuran picks Small-molecule inhibitors of histone deacetylase for the treatment of cancer and non-cancer diseases: a patent review (2011 – 2013) by Sergio Valente & Antonello Mai as the highlight of the April issue. Read it FREE here.
  • Editor picks review on novel antifungal agents as highlight of the EOTP March issue!

    March 10, 2022
    Fungal infections represent a worldwide health problem and resistance to many of the clinically used drugs is reported more and more frequently. The review presents a discussion of the patent literature in the last three years, with a focus on compounds with broad efficacy, good pharmacologic profiles, absence of drug-drug interactions, etc. Click HERE to read.
  • First half of the First-in-Class cross-series themed issue available now!

    February 17, 2022
    First-in-Class drugs and their novel mechanisms of action are the focus of the first Expert Opinion and Expert ReviewsCross-series themed issue. All articles will be published in their respective journals between January and April 2022 so half of them are already available!
  • Supuran chooses review on novel thiazole derivatives as his Editor’s Pick for February!

    February 10, 2022
    The Editor-in-Chief of Expert Opinion on Therapeutic Patents, Claudiu Supuran, has chosen Novel thiazole derivatives: a patent review (2008-2012; Part 1) by Alberto Leoni, Alessandra Locatelli, Rita Morigi & Mirella Rambaldi as his Editor’s Pick for the February issue.
  • Supuran chooses article on Tubulin inhibitors as January’s Editor’s Pick!

    January 16, 2022
    Professor Claudiu Supuran, Editor-in-Chief of Expert Opinion on Therapeutic Patents, has chosen Tubulin inhibitors: a patent review by Yi-Min Liu , Hsiao-Ling Chen , Hsueh-Yun Lee & Jing-Ping Liou as his Editor’s Pick for the January issue.
  • Expert Opinion and Expert Reviews are now on facebook!

    December 18, 2013
    The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!
  • This month in Expert Opinion…..

    December 13, 2013

    Five articles from the Expert Opinion Series are within the top 100 most accessed articles from the Informa healthcare journal portfolio in November 2013

  • Expert Opinion posts TWO articles on Rho kinase inhibitors early online!

    December 6, 2013
    If you want to know more about Rho kinase inhibitors, look no further! Expert Opinion on Therapeutic Patents and Expert Opinion on Investigational Drugs have both recently posted articles on these compounds from different points of view.
  • Claudiu Supuran picks his highlight of the December issue of EOTP!

    December 4, 2013
    Editor-in-Chief of Expert Opinion on Therapeutic Patents, Prof. Claudiu Supuran, chooses Inhibitors of cathepsin G: a patent review (2005 to present) by Paulina Kosikowska & Adam Lesner as his Editor’s Pick for the December issue.
  • Supuran picks review on AT1 antagonists for November 2013 issue of EOTP!

    November 15, 2013
    Editor-in-Chief of Expert Opinion on Therapeutic Patents, Professor Claudiu Supuran, has chosen AT1 antagonists: a patent review (2008-2012) by Thomas Mavromoustakos, George Agelis & Serdar Durdagi as his Editor’s Pick for the November issue.
  • This week in Expert Opinion

    November 8, 2013
    This week in Expert Opinion, we look at the emerging treatments for some of the world’s most prevalent diseases covering: autoimmune, infectious and cardiovascular disease. Click above to find out more.
  • Editor-in-Chief of Expert Opinion on Therapeutic Patents is No. 1!

    November 6, 2013
    Professor Claudiu Supuran, Editor in Chief of EOTP, tops the list of most cited authors in the Pharmacology and Pharmacy category. 
  • Editor-in-Chief picks update on Estrogen receptor ligands as highlight

    October 8, 2013
    Editor-in-Chief, Prof. Claudiu Supuran, has chosen Estrogen receptor ligands: a patent review update by Ilaria Paterni, Simone Bertini, Carlotta Granchi, Marco Macchia & Filippo Minutolo as his Editor’s Pick for the October 2013 issue of Expert Opinion on Therapeutic Patents!
  • Editorial Highlight for September 2013

    August 23, 2013
    Non-peptidic δ opioid receptor agonists and antagonists (2000 – 2012) by Hideaki Fujii, Toshihiro Takahashi and Hiroshi Nagase
  • Editorial Highlight for August 2013

    July 31, 2013
    PDE4 inhibitors: a review of current developments (2010-2012) by Amadeu Gavaldà & Richard S Roberts
  • European patent for Pfizer’s Viagra expires – 21st June 2013

    June 24, 2013

    European patent for Pfizer’s Viagra expires – 21st June 2013

    Despite extending the patent protection on Viagra (sildenafil) in the US until 2020, Pfizer now has to face the effects of patent expiration in the UK and other countries in Europe. 

  • Editor’s Pick for July 2013

    June 21, 2013

    5-Lipoxygenase inhibitors: a review of recent patents (2010 – 2012) by Bettina Hofmann & Dieter Steinhilber

  • Themed issue (June) – A note from the Guest Editor

    May 16, 2013
    A note from the Guest Editor, Professor Claudiu Supuran, about the Carbonic Anhydrase Inhibitors themed issue.
  • Editor’s Pick for May 2013

    April 17, 2013
    Sigma receptor modulators: a patent review by Simona Collina, Raffaella Gaggeri, Annamaria Marra, Andrea Bassi, Sara Negrinotti, Francesca Negri & Daniela Rossi
  • Editor’s Pick for April 2013

    March 15, 2013

    PARP INHIBITORS IN CANCER THERAPY: AN UPDATE by Gianluca Papeo, Elena Casale, Alessia Montagnoli, and Alessandra Cirla

  • Editor’s Pick for March 2013

    February 20, 2013
    Novel 1H-1,2,3-, 2H-1,2,3-, 1H-1,2,4- and 4H-1,2,4-triazole derivatives: a patent review (2008-2011) by Vitor F Ferreira et al
  • Editor’s pick for February 2013

    January 17, 2013
    Novel prostaglandin receptor modulators – Part II: EP receptor modulators; a patent review (2002 – 2012) by Daniel Flesch, Daniel Merk, Christina Lamers & Manfred Schubert-Zsilavecz is the article pick of the month from Editor-in-Chief Claudiu Supuran.

  • Editor’s pick for January 2013

    December 14, 2012
    Sulfatase inhibitors: a patent review by Spencer J Williams is our Editor’s pick from Claudiu T. Supuran for the January 2013 issue of Expert Opinion on Therapeutic Patents.
  • Editor’s pick for November 2012

    October 15, 2012
    Patented TGR5 modulators: a review (2006 – present) by Antimo Gioiello, Emiliano Rosatelli, Roberto Nuti, Antonio Macchiarulo & Roberto Pellicciari is the pick of the November issue from our Editor-in-Chief Claudiu Supuran.

  • Editor’s Pick October 2012 – what’s new in flu?

    September 27, 2012
    Flavonoids in the therapy and prophylaxis of flu: a patent review by Sônia S Costa, José Nelson S S Couceiro, Isabel Cristina V Silva, David do C Malvar, Marcela A S Coutinho, Luiza Maria M Camargo, Michelle F Muzitano & Frederico A Vanderlinde is our Editor’s pick of the month for the October issue.
  • Editor’s Pick September 2012 – Targeting autophagy

    August 20, 2012

    Novel pharmacological modulators of autophagy and therapeutic prospects by Bischoff, Josset and Dumont is the Editor’s pick for September in EOTT.

    This interesting paper reviews the scientific and patent literature of the last 4 years (2008-2012) in the field of autophagy and modulators (inhibitors or enhancers) of this phenomenon.

  • Let’s be clear – Expert Opinion on ethical publishing

    March 27, 2012
    In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.
  • Editor’s Pick February 2012

    February 20, 2012

    “Compositions and methods for treatment of Parkinson’s disease: a patent evaluation of WO2011/102847A1” Valerio Chiurchiù, Mauro Maccarrone, & Antonio Orlacchio

    An evaluation of the application: WO2011/102847A1, which discusses novel and interesting methods to treat Parkinson’s disease (PD).  The invention under discussion centres on a method for treating or preventing PD by increasing the level of at least one protein involved in an autoregulatory pathway, which is fundamental during mDA neurons differentiation.

    For access to the article summary, please click here.

  • Editor’s Pick January 2012

    January 13, 2012

    “Tachykinin NK2 receptor antagonists. A patent review (2006 – 2010)” Maria Altamura

    In this article, Dr Maria Altamura discusses the potential of Tachykinin NK2 receptor antagonists in the treatment of various gastrointestinal, genitourinary and CNS diseases. An overview of patenting activity in the last 5 years is provided, including an evaluation of the patents novelty, proposed indications and clinical studies. Furthermore, patents claiming new therapeutic indications are included in a dedicated section.

    For access to the article summary, please click here.

  • Expert Opinion Podcast with Dr Patrick Gunning

    September 30, 2011
    Expert Opinion has just recorded a Podcast with Dr Patrick Gunning from the University of Toronto. Dr Gunning discussed his paper entitled ‘Signal transducer and activator of transcription 3 inhibitors: a patent review’ published in the January 2011 issue of Expert Opinion on Therapeutic Patents. Dr Gunning describes the molecular strategies that have been employed to inhibit aberrantly activated Stat3 protein activity in human cancers. Although there have been great developments in this field, no Stat3 inhibitor has yet gained FDA approval.
  • Expert Opinion Podcast with Dr Philip Carpino

    September 23, 2011
    This month, Expert Opinion has recorded a Podcast with Dr Philip Carpino from Pfizer. Dr Carpino discussed his paper entitled ‘Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature’ published in the December 2010 issue of Expert Opinion on Therapeutic Patents. Dr Carpino describes the competitive landscape in the area and the pharmacological targets that pharmaceutical companies and academic institutions are focusing on. The pharmaceutical industry has responded to the diabetes crisis by investigating multiple targets and many different pathways and it remains to be seen if this flurry of patent activity has lead to more compounds in clinical development.